CD8A and metastatic melanoma: A longitudinal follow-up of a patient with metastatic melanoma who relapsed upon interleukin-2 treatment revealed an activation of the β-catenin pathway, associated with the absence of infiltrating CD8+ T cells and decreased chemokine expression in the recurrent tumor (23).